Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Executive Summary

Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.

You may also be interested in...



Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill

By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.

FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research

Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.

US FDA Tiptoes Further Into Off-Label Use Discussions With CURE ID App

App allows clinicians to discuss off-label treatments, but information is intended to be hypothesis-generating, not for regulatory use.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS119862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel